Akademik Veri Yönetim Sistemi
ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, cilt.13, sa.9, ss.1008-1012, 2022 (ESCI)
Aim: Repurposing non-cancer drugs may be a new hope for cancer treatment. It has many advantages. Sunitinib is a tyrosine kinase inhibitor that inhibits vascular epithelial growth factor receptors. It is used for metastatic renal cell carcinoma (mRCC) treatment. We planned to investigate the effects of noncancer drugs like calcium channel blockers (CCBs) and others on sunitinib in mRCC patients.Material and Methods: We retrospectively scanned the files of mRCC patients applied to our center between January 2013 and April 2019 and used sunitinib. We analyzed some parameters of these patients and their effects on overall survival (OS) and progression-free survival (PFS). A chi 2 or Fisher's exact test, Kaplan-Meier and Cox regressions were used in the statistical analysis.Results: Thirty-five patients were examined, 15 of them were taking CCB for arterial hypertension and sunitinib for RCC, simultaneously. The 36-Months OS rates of CCB users and non-users were 61.1 and 38.9%, respectively (OR:5.1, 95% CI: 1.17-22.1, P=.041). The 24-Months PFS rates of CCB users and non-user were 68.8 and 31.3%, respectively (OR:8.25, 95% CI: 1.79-38.01, P=.007).Discussion: It is a new idea to combine the targeted cancer drugs and non-cancer drugs for better anticancer outcomes. There were 36-months OS and 24-months PFS advantages with simultaneously taking CCBs and sunitinib. Sunitinib and CCBs combination should be studied in preclinical studies and their additive effect mechanisms should be clarified.